{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT00986401",
      "orgStudyIdInfo": {
        "id": "MA-SXR-09-002"
      },
      "organization": {
        "fullName": "Allergan",
        "class": "INDUSTRY"
      },
      "briefTitle": "Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects",
      "officialTitle": "Safety and Tolerability of Trospium Chloride Metformin Hydrochloride in Healthy Subjects"
    },
    "statusModule": {
      "statusVerifiedDate": "2011-11",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2009-10"
      },
      "primaryCompletionDateStruct": {
        "date": "2009-11",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2009-11",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2009-09-16",
      "studyFirstSubmitQcDate": "2009-09-29",
      "studyFirstPostDateStruct": {
        "date": "2009-09-30",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2011-11-16",
      "resultsFirstSubmitQcDate": "2011-11-16",
      "resultsFirstPostDateStruct": {
        "date": "2011-12-19",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2011-11-16",
      "lastUpdatePostDateStruct": {
        "date": "2011-12-19",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Allergan",
        "class": "INDUSTRY"
      }
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered."
    },
    "conditionsModule": {
      "conditions": [
        "Healthy"
      ],
      "keywords": [
        "Adults"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "CROSSOVER",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 44,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Glucophage® then Sanctura XR® (AB)",
          "type": "EXPERIMENTAL",
          "description": "Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.",
          "interventionNames": [
            "Drug: Metformin hydrochloride (Glucophage®)"
          ]
        },
        {
          "label": "Sanctura XR® then Glucophage® (BA)",
          "type": "EXPERIMENTAL",
          "description": "Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.",
          "interventionNames": [
            "Drug: Trospium Chloride (Sanctura XR®)"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Trospium Chloride (Sanctura XR®)",
          "description": "extended release, 60 mg, oral daily",
          "armGroupLabels": [
            "Sanctura XR® then Glucophage® (BA)"
          ],
          "otherNames": [
            "Sanctura XR® 60 mg"
          ]
        },
        {
          "type": "DRUG",
          "name": "Metformin hydrochloride (Glucophage®)",
          "description": "immediate release, 500mg",
          "armGroupLabels": [
            "Glucophage® then Sanctura XR® (AB)"
          ],
          "otherNames": [
            "Glucophage®"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®",
          "description": "Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.",
          "timeFrame": "34 Days"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®",
          "description": "Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.",
          "timeFrame": "34 Days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Weight within +/-30% of ideal body weight for height and frame size\n* Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 1 months prior to the screening visit).\n* Willing to abstain from caffeine-containing food and beverages for 24-hours prior to dosing, alcohol-containing food and beverage for 48 hours prior to dosing, and Seville oranges (eg orange marmalade), grapefruit, or grapefruit juice for 7 days prior to the dosing and abstain from all throughout the study.\n* Willing to abstain from taking medications (with the exception of hormonal contraceptives) and nonprescription medication including vitamins, food supplements, and herbal preparations for 7 days prior to Day-1 of the first treatment period and throughout the study.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease\n* Known allergy or sensitivity to the study medication(s) (Trospium, Metformin)or its components\n* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.\n* History of myasthenia gravis or closed-angle glaucoma.\n* Considering or scheduled to undergo any surgical procedure during the study.\n* History of alcohol or substance abuse within 1 year prior to Day-1 of the first treatment period.\n* History of serious mental or physical illness.\n* Donated in excess of 500 mL of blood in the 30 days prior to the screening visit.\n* Required treatment with any medications, either prescription or nonprescription (including vitamins, antacids, acid-reducers, food supplements, and herbal preparations, excluding hormonal contraceptives), within 7 days prior to Day-1 of the first treatment period during the study.\n* Had an acute illness within 5 days prior to Day-1 of the treatment period.\n* Had a history of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies.\n* Planned radiologic study requiring intravenous contrast administration of iodinated contrast material during the study period Serum Creatinine greater than 1.4 mg/dL.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "45 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Medical Director",
          "affiliation": "Allergan",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona",
          "country": "United States",
          "geoPoint": {
            "lat": 33.41477,
            "lon": -111.90931
          }
        }
      ]
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Glucophage® Then Sanctura XR® (AB)",
          "description": "Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days."
        },
        {
          "id": "FG001",
          "title": "Sanctura XR® Then Glucophage® (BA)",
          "description": "Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days."
        }
      ],
      "periods": [
        {
          "title": "Period 1",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "22"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "22"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "22"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "21"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        },
        {
          "title": "Period 2",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "22"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "21"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "22"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "21"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Glucophage® Then Sanctura XR® (AB)",
          "description": "Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days."
        },
        {
          "id": "BG001",
          "title": "Sanctura XR® Then Glucophage® (BA)",
          "description": "Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days."
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "22"
            },
            {
              "groupId": "BG001",
              "value": "22"
            },
            {
              "groupId": "BG002",
              "value": "44"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age Continuous",
          "paramType": "MEDIAN",
          "dispersionType": "FULL_RANGE",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "31.0",
                      "lowerLimit": "18",
                      "upperLimit": "44"
                    },
                    {
                      "groupId": "BG001",
                      "value": "30.2",
                      "lowerLimit": "18",
                      "upperLimit": "44"
                    },
                    {
                      "groupId": "BG002",
                      "value": "31.0",
                      "lowerLimit": "18",
                      "upperLimit": "44"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10"
                    },
                    {
                      "groupId": "BG001",
                      "value": "9"
                    },
                    {
                      "groupId": "BG002",
                      "value": "19"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "12"
                    },
                    {
                      "groupId": "BG001",
                      "value": "13"
                    },
                    {
                      "groupId": "BG002",
                      "value": "25"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) Following Oral Administration of Glucophage®",
          "description": "Maximum Plasma Level (Cmax) of Metformin Hydrochloride (Glucophage®) following oral administration of Glucophage® alone and in combination with SanturaXR®. Plasma is the fluid portion of the blood.",
          "populationDescription": "Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "Nanograms per milliliter (ng/mL)",
          "timeFrame": "34 Days",
          "groups": [
            {
              "id": "OG000",
              "title": "Glucophage®",
              "description": "Glucophage®"
            },
            {
              "id": "OG001",
              "title": "Glucophage® + Sanctura XR®",
              "description": "Glucophage® + Sanctura XR®"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "43"
                },
                {
                  "groupId": "OG001",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "739",
                      "spread": "263"
                    },
                    {
                      "groupId": "OG001",
                      "value": "753",
                      "spread": "252"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR®",
          "description": "Maximum Plasma Level (Cmax) of Trospium Chloride (Sanctura XR®) Following Oral Administration of Sanctura XR® alone and in combination with Glucophage®. Plasma is the fluid portion of the blood in which the cells are suspended.",
          "populationDescription": "Intent-to-treat, which includes all patients who started the study (randomized). One patient was not included in the analysis due to early discontinuation.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "Nanograms per milliliter (ng/mL)",
          "timeFrame": "34 Days",
          "groups": [
            {
              "id": "OG000",
              "title": "Sanctura XR®",
              "description": "Sanctura XR®"
            },
            {
              "id": "OG001",
              "title": "Sanctura XR® + Glucophage®",
              "description": "Sanctura XR® + Glucophage®"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "44"
                },
                {
                  "groupId": "OG001",
                  "value": "43"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.87",
                      "spread": "1.44"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1.17",
                      "spread": "0.71"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "description": "The safety population was used to calculate the number of participants at risk for SAEs and AEs and is the total number of patients that were randomized AND treated.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Glucophage®",
          "description": "Glucophage®",
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 43,
          "otherNumAffected": 10,
          "otherNumAtRisk": 43
        },
        {
          "id": "EG001",
          "title": "Sanctura XR®",
          "description": "Sanctura XR®",
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 44,
          "otherNumAffected": 3,
          "otherNumAtRisk": 44
        },
        {
          "id": "EG002",
          "title": "Sanctura XR® in Combination With Glucophage®",
          "description": "Sanctura XR® in combination with Glucophage®",
          "seriousNumAffected": 0,
          "seriousNumAtRisk": 44,
          "otherNumAffected": 13,
          "otherNumAtRisk": 44
        }
      ],
      "otherEvents": [
        {
          "term": "Abdominal pain upper",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA (12.0)",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 44
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 44
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA (12.0)",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 44
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 44
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA (12.0)",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG001",
              "numAffected": 3,
              "numAtRisk": 44
            },
            {
              "groupId": "EG002",
              "numAffected": 7,
              "numAtRisk": 44
            }
          ]
        },
        {
          "term": "Nasal congestion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA (12.0)",
          "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 44
            },
            {
              "groupId": "EG002",
              "numAffected": 3,
              "numAtRisk": 44
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictiveAgreement": false
      },
      "pointOfContact": {
        "title": "Vice President, Medical Affairs",
        "organization": "Allergan, Inc.",
        "email": "clinicaltrials@allergan.com",
        "phone": "714-246-4500"
      }
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-10-28"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C003330",
          "term": "trospium chloride"
        },
        {
          "id": "D008687",
          "term": "Metformin"
        }
      ],
      "ancestors": [
        {
          "id": "D001645",
          "term": "Biguanides"
        },
        {
          "id": "D006146",
          "term": "Guanidines"
        },
        {
          "id": "D000578",
          "term": "Amidines"
        },
        {
          "id": "D009930",
          "term": "Organic Chemicals"
        }
      ]
    }
  },
  "hasResults": true
}